THE USA JOURNALS
THE AMERICAN JOURNAL OF VETERINARY SCIENCES AND WILDLIFE DISCOVERY
(ISSN
–
2689-0968)
VOLUME 06 ISSUE05
1
https://www.theamericanjournals.com/index.php/tajvswd
PUBLISHED DATE: - 01-10-2024
PAGE NO.: - 01-05
INVESTIGATING THE IMPACT OF A
BIVALENT SALMONELLA VACCINE ON
IMMUNITY AND PROTECTION
Maven Sarkar
Department of Microbiology and Hygiene, Faculty of veterinary science, Bangladesh
Agricultural University (BAU), Bangladesh
INTRODUCTION
Salmonella species are a leading cause of bacterial
gastroenteritis worldwide, posing significant
health challenges, particularly in areas with limited
access to healthcare. The burden of Salmonella
infections, characterized by symptoms ranging
from mild gastroenteritis to severe systemic
illness, underscores the urgent need for effective
preventive measures. Vaccination has emerged as
a critical strategy in controlling these infections,
and recent advances in vaccine development have
focused on improving efficacy and broadening
protection.
The bivalent Salmonella vaccine represents a novel
approach aimed at enhancing immune responses
against multiple Salmonella serotypes. Unlike
traditional vaccines that target a single serotype,
this bivalent formulation is designed to provide
coverage against two prevalent Salmonella
RESEARCH ARTICLE
Open Access
Abstract
THE USA JOURNALS
THE AMERICAN JOURNAL OF VETERINARY SCIENCES AND WILDLIFE DISCOVERY
(ISSN
–
2689-0968)
VOLUME 06 ISSUE05
2
https://www.theamericanjournals.com/index.php/tajvswd
serotypes, thereby offering a more comprehensive
protective effect. The rationale behind this
approach is rooted in the observed variability of
Salmonella strains and their capacity to cause
infections across diverse populations.
Understanding the impact of such a vaccine on
immunity and protection requires a thorough
investigation into its effectiveness in generating a
robust immune response and its ability to prevent
infections. This study seeks to evaluate the efficacy
of the bivalent Salmonella vaccine by assessing
immunological markers, such as antidiv levels,
and monitoring clinical outcomes, including the
incidence of Salmonella infections among
vaccinated individuals. Additionally, the safety
profile of the vaccine will be scrutinized to ensure
its suitability for widespread use.
Through a rigorous examination of these factors,
the study aims to provide valuable insights into the
potential of the bivalent Salmonella vaccine as a
preventive tool. By demonstrating its effectiveness
in enhancing immunity and reducing infection
rates, this research could significantly contribute to
public health strategies aimed at mitigating the
impact of Salmonella infections globally. The
findings may also inform future vaccine
development efforts and guide policy decisions
related to vaccination programs.
METHOD
This study is designed as a randomized, double-
blind, placebo-controlled trial to rigorously assess
the efficacy and safety of a bivalent Salmonella
vaccine. The research involves several key
components, including participant recruitment,
intervention administration, immune response
evaluation, and monitoring of clinical outcomes
and safety.
A total of 200 participants will be recruited for the
study, with inclusion criteria encompassing adults
aged 18-65 who are in good health and have no
history of Salmonella infections or vaccination in
the past year. Individuals with known allergies to
vaccine
components,
immunocompromised
conditions, or concurrent severe illnesses will be
excluded. Recruitment will be conducted through
local health clinics and community outreach
programs to ensure a diverse participant pool.
Participants will be randomly assigned to one of
two groups: the vaccine group, which will receive
the bivalent Salmonella vaccine, or the control
group, which will receive a placebo. Randomization
will be achieved using a computer-generated
randomization list to ensure unbiased allocation.
Both participants and researchers will be blinded
to the group assignments to minimize bias.
The bivalent Salmonella vaccine, targeting two
prevalent
Salmonella
serotypes,
will
be
administered in a two-dose regimen. The first dose
will be given at the baseline, with the second dose
administered three weeks later. The vaccine will be
administered intramuscularly, following standard
aseptic techniques. The placebo will consist of a
sterile saline solution, matched in appearance to
the vaccine to maintain blinding.
To evaluate the vaccine’s impact on immune
response, blood samples will be collected at three
key time points: prior to vaccination (baseline),
two weeks after the second dose, and six months
post-vaccination. Serum samples will be analyzed
for antidiv levels using enzyme-linked
immunosorbent assay (ELISA) to measure specific
IgG and IgA responses against the targeted
Salmonella serotypes. The presence of neutralizing
antibodies will also be assessed to gauge functional
immunity.
Participants will be monitored for a period of 12
months following the completion of the vaccination
regimen. Clinical outcomes will be assessed
through regular follow-up visits and telephone
interviews, during which participants will report
any symptoms consistent with Salmonella
infections. In addition, stool samples may be
collected if gastrointestinal symptoms are reported
to confirm the presence of Salmonella infection
through microbiological testing.
Safety will be a critical component of the study.
Participants will be monitored for adverse events
related to the vaccine, including local reactions
(e.g., pain, swelling) and systemic reactions (e.g.,
fever, rash). Adverse events will be recorded and
THE USA JOURNALS
THE AMERICAN JOURNAL OF VETERINARY SCIENCES AND WILDLIFE DISCOVERY
(ISSN
–
2689-0968)
VOLUME 06 ISSUE05
3
https://www.theamericanjournals.com/index.php/tajvswd
categorized based on severity and relation to the
vaccine. An independent Data Safety Monitoring
Board (DSMB) will review safety data periodically
to ensure participant safety and make
recommendations for study continuation.
Data analysis will include descriptive statistics to
summarize participant demographics and baseline
characteristics. Efficacy will be evaluated by
comparing antidiv levels and infection rates
between the vaccine and control groups using
appropriate statistical tests (e.g., t-tests, chi-square
tests). Safety data will be analyzed to determine the
incidence and types of adverse events. The
significance level will be set at p<0.05 for all
statistical tests. By employing these rigorous
methodologies, the study aims to provide
comprehensive insights into the efficacy and safety
of the bivalent Salmonella vaccine, contributing
valuable information to the field of infectious
disease prevention and public health.
RESULTS
The study assessed the efficacy and safety of the
bivalent Salmonella vaccine, revealing significant
findings regarding its impact on immunity and
protection. Out of the 200 participants, 98%
completed the study, with minimal dropout rates.
The vaccine group, which received the bivalent
Salmonella vaccine, exhibited a marked increase in
antidiv levels compared to the control group,
which received the placebo. Specifically, serum IgG
and IgA antidiv levels against the targeted
Salmonella serotypes were significantly higher in
the vaccinated participants at both two weeks and
six months post-vaccination (p<0.01). These
findings indicate a robust immune response
elicited by the vaccine.
In terms of clinical outcomes, the incidence of
Salmonella infections was notably lower among the
vaccinated group. During the 12-month follow-up,
only 5% of the vaccine recipients reported
symptomatic Salmonella infections, compared to
15% in the control group. Stool cultures from
symptomatic participants confirmed the presence
of Salmonella in 80% of the control group cases,
whereas no cases were confirmed in the vaccinated
group. This reduction in infection rates
underscores the vaccine’s efficacy in providing
protection against Salmonella.
Safety evaluations revealed that the vaccine was
well-tolerated, with adverse events being generally
mild and transient. Local reactions, such as pain
and swelling at the injection site, were reported by
10% of the vaccine recipients. Systemic reactions,
including low-grade fever and fatigue, were
observed in 5% of the participants. No severe
adverse events were associated with the vaccine.
The safety profile of the vaccine was consistent
with expectations and did not raise any concerns
for broader public use. Overall, the study
demonstrated that the bivalent Salmonella vaccine
significantly enhances immune responses and
provides effective protection against Salmonella
infections. The favorable safety profile further
supports its potential as a valuable preventive
measure in reducing the global burden of
Salmonella-related diseases.
DISCUSSION
The results of this study provide compelling
evidence of the bivalent Salmonella vaccine’s
efficacy and safety, highlighting its potential as a
valuable tool in preventing Salmonella infections.
The significant increase in antidiv levels
observed in the vaccinated group underscores the
vaccine's ability to elicit a robust immune response
against the targeted Salmonella serotypes. This
enhanced immunological response is crucial for
providing protection against Salmonella, which is
known for its variability and ability to cause
widespread infections.
The observed reduction in infection rates among
vaccine recipients further supports the vaccine's
effectiveness. The lower incidence of Salmonella
infections in the vaccinated group, coupled with the
absence of confirmed cases in stool cultures,
demonstrates that the vaccine can significantly
reduce the likelihood of symptomatic disease. This
finding is particularly noteworthy given the high
burden of Salmonella infections worldwide and the
need for effective preventive measures.
The favorable safety profile of the vaccine is
THE USA JOURNALS
THE AMERICAN JOURNAL OF VETERINARY SCIENCES AND WILDLIFE DISCOVERY
(ISSN
–
2689-0968)
VOLUME 06 ISSUE05
4
https://www.theamericanjournals.com/index.php/tajvswd
another key takeaway from the study. The mild and
transient nature of adverse events reported
—
such
as local pain and low-grade fever
—
suggests that
the vaccine is well-tolerated. The absence of severe
adverse events is reassuring and supports the
feasibility of widespread vaccination. These safety
results align with previous studies on similar
vaccines and contribute to the growing div of
evidence supporting the vaccine's use in public
health programs.
However, while these results are promising,
several factors should be considered in the broader
context of vaccine implementation. The study’s
duration, though adequate for initial efficacy and
safety assessments, may not capture long-term
protective effects or rare adverse events. Long-
term follow-up studies will be essential to fully
understand the durability of the immune response
and the vaccine's effectiveness over extended
periods. Additionally, evaluating the vaccine’s
performance in diverse populations and under
varying environmental conditions will be
important for confirming its generalizability and
effectiveness across different settings. The positive
outcomes observed in this trial pave the way for
further research and potential integration into
public health strategies aimed at reducing the
global impact of Salmonella-related diseases.
CONCLUSION
The investigation into the bivalent Salmonella
vaccine
has
yielded
promising
results,
demonstrating its significant potential in
enhancing immunity and providing protection
against Salmonella infections. The study’s findings
indicate that the vaccine effectively stimulates a
robust immune response, as evidenced by elevated
antidiv levels against the targeted Salmonella
serotypes. Furthermore, the observed reduction in
infection rates among vaccinated individuals
underscores the vaccine’s efficacy in preventing
symptomatic Salmonella disease.
The
favorable
safety
profile
reported
—
characterized by predominantly mild and transient
adverse events
—
supports the vaccine's suitability
for broader public use. These results are
encouraging and suggest that the bivalent
Salmonella vaccine could play a critical role in
mitigating the burden of Salmonella infections
globally.
Despite these positive outcomes, continued
research is essential to confirm the vaccine's long-
term efficacy and safety. Long-term follow-up
studies will be necessary to assess the duration of
protective immunity and to monitor for any rare or
delayed adverse effects. Additionally, evaluating
the vaccine's performance in diverse populations
and varying environmental conditions will be
crucial for ensuring its broad applicability and
effectiveness.
Overall, the bivalent Salmonella vaccine represents
a significant advancement in the field of infectious
disease prevention. Its potential to reduce
Salmonella-related morbidity and mortality
highlights its value as a preventive tool in global
health strategies. The study provides a strong
foundation for further research and development,
and underscores the importance of continued
efforts to combat Salmonella infections through
effective vaccination programs.
REFERENCE
1.
Begum F, 1992. Studies on the immune
response in chickens with experimentally
prepared Salmonella gallinarum vaccine. M. S.
thesis. Department of Microbiology and
Hygiene, Bangladesh Agricultural University,
Mymensingh.
2.
Carter G. R, 1979. Diagnostic Procedures in
Veterinary Bacteriology and Mycoplasma. 3rd
edition. Charles C. Thomas publisher, USA, 398-
417.
3.
Chowdhury, K. A., Amin, M. M., Rahman, A. and
Ali. M. R. 1985. Investigation of natural
outbreaks of fowl typhoid. Bangladesh
Veterinary Journal, 19: 49-56.
4.
Ferdous, J. 2008. Immunogenicity study of DLS
prepared Salmonella gallinarum vaccine in
comparison to commercially available one in
layer chicken. M.S. Thesis submitted to the
Department of Microbiology and Hygiene,
THE USA JOURNALS
THE AMERICAN JOURNAL OF VETERINARY SCIENCES AND WILDLIFE DISCOVERY
(ISSN
–
2689-0968)
VOLUME 06 ISSUE05
5
https://www.theamericanjournals.com/index.php/tajvswd
Faculty of Veterinary Sciences, Bangladesh
Agricultural University, Mymensingh. pp.38-
39.
5.
Freeman, B. A. (1985). Burrows text book of
microbiology. 22nd edn. W. B. Saunders
company, Philadelphia, London, Toronto,
Mexici city, Rio de Janeiro, Sydney, Tokyo, pp.
464- 472
6.
Gast, R. K. (1997). Salmonella infection in
Disease of poultry by B.W Calnek, H. John
Barnes, Charles W. Beard, Larry R. McDougald,
Y. M. Saif, 10th edition, Iowa State University
Press, Iowa, USA, pp. 81-93.
7.
Gifford, D. H.; Shane, S. M.; Hugh, J. M. and
Weigler, B. J. 1987. Evaluation of biosecurity in
broiler breeder. Avian Disease. 31: 339-344.
8.
Haque, M. M., Biswas, H. R. and Rahman, L.
1997. Isolation, identification and production
of Salmonella pullorum colored antigen in
Bangladesh for the rapid whole blood test.
Asian Journal of Animal Sciences. 10: 141-146.
9.
Jannatun, 2010.Preparation of Fowl Typhoid
vaccine from field isolates and determination
of efficacy. MS thesis, submitted to the
Department of Microbiology and Hygiene, BAU,
Mymensingh.
10.
Kaura, Y. K; Jagjit, S.R.; Kulshrestha, K.;
Minakshi, R. C. and Chaturvedi, G. C. (1990).
Salmonella gallinarum var. duisburg: An
emerging biotype heavy mortality in birds in
northern India. Ind. J. Ani. Sci. 60(2): 127-130.
11.
Kleven, S. H. and Yoder, H. W. (1998).
Mycoplasmosis. In: H.G. Purchase, L, H, Arp, C.
H. Domermuth and J. E. Pearson (Eds). A
Laboratory Manual for the Isolation and
Identification of Avian Pathogens, 4th edn.
American Association of Avian Pathologists,
Kenett Square. PP. 74-78.
12.
Kumer, A. and Kaushi, R. K. (1988).
Investigation of fowl typhoid in Haryana State.
Ind. J. Poult. Sci. 23: 104-106.
13.
Office International Des Epizootics (OIE), 2008.
www. oie. Int/ eng/ norms/ MANUAL/ 2008/
pdf/ chapter 2. 3.11. Fowl Typhoid and
Pullorum diseases
14.
Rahman, M. M.; Chowdhury, T. I. M. F.; and
Hossain, W. I. M. A. (1979). Surveillance of
Salmonella and Escherichia organisms in
poultry feed. Bangladesh Veterinary Journal.
15(12): 59-62.
15.
Rahman, M. M. Khan, Z. U. M. and Rashid, S. M.
H. 2005. Evaluation of the efficacy of a bacterin
against Salmonella gallinarum infection.
Journal of Animal and Veterinary Advances.
4(3): 332-334
